771,410 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by Glenview Capital Management LLC

Glenview Capital Management LLC purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 771,410 shares of the medical equipment provider’s stock, valued at approximately $94,197,000. Glenview Capital Management LLC owned about 0.38% of Zimmer Biomet Holdings as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Alpha Windward LLC boosted its position in Zimmer Biomet Holdings by 1.1% in the first quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider’s stock worth $202,000 after buying an additional 18 shares during the period. Sandy Spring Bank boosted its position in Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares during the period. Parkside Financial Bank & Trust boosted its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares during the period. Cleararc Capital Inc. boosted its position in Zimmer Biomet Holdings by 0.5% in the first quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock worth $598,000 after buying an additional 25 shares during the period. Finally, Enterprise Financial Services Corp boosted its position in Zimmer Biomet Holdings by 1.0% in the first quarter. Enterprise Financial Services Corp now owns 2,637 shares of the medical equipment provider’s stock worth $322,000 after buying an additional 27 shares during the period. 84.17% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 126.49 on Wednesday. The company has a 50-day moving average of $123.43 and a 200 day moving average of $117.75. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.21. The stock has a market cap of $25.51 billion, a price-to-earnings ratio of 51.78 and a beta of 1.21.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.02. The business had revenue of $1.98 billion during the quarter, compared to analyst estimates of $1.96 billion. Zimmer Biomet Holdings had a return on equity of 16.80% and a net margin of 6.36%. The firm’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.00 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.54 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Friday, June 23rd will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.76%. Zimmer Biomet Holdings’s dividend payout ratio is 39.67%.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://baseballnewssource.com/markets/771410-shares-in-zimmer-biomet-holdings-inc-nysezbh-acquired-by-glenview-capital-management-llc/1180058.html.

A number of research firms have recently weighed in on ZBH. BMO Capital Markets reaffirmed a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet Holdings in a research note on Tuesday. Guggenheim raised shares of Zimmer Biomet Holdings from a “neutral” rating to a “buy” rating in a research note on Wednesday. Citigroup Inc. upped their price target on shares of Zimmer Biomet Holdings from $108.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, June 9th. Jefferies Group LLC reissued a “buy” rating and issued a $148.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, June 30th. Finally, Royal Bank Of Canada increased their price objective on shares of Zimmer Biomet Holdings from $133.00 to $140.00 and gave the company an “outperform” rating in a research note on Wednesday, June 21st. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zimmer Biomet Holdings has a consensus rating of “Buy” and an average price target of $137.69.

In other news, insider David C. Dvorak sold 87,331 shares of Zimmer Biomet Holdings stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $116.47, for a total transaction of $10,171,441.57. Following the completion of the sale, the insider now directly owns 381,886 shares in the company, valued at approximately $44,478,262.42. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Chad F. Phipps sold 6,200 shares of Zimmer Biomet Holdings stock in a transaction dated Friday, May 5th. The shares were sold at an average price of $116.76, for a total value of $723,912.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 111,262 shares of company stock valued at $13,103,927. 1.07% of the stock is owned by corporate insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base


Leave a Reply

 
© 2006-2017 BBNS.